Literature DB >> 17914967

Mutations in ISDR of NS5A gene influence interferon efficacy in Chinese patients with chronic hepatitis C virus genotype 1b infection.

Chuanlai Shen1, Ting Hu, Ling Shen, Lei Gao, Wei Xie, Jianqiong Zhang.   

Abstract

BACKGROUND AND AIM: The interferon sensitivity determining region (ISDR) in the non-structural 5A protein (NS5A) gene of hepatitis C virus genotype 1b (HCV-1b) has been demonstrated in Japanese patients; however, contradictory data have been reported from other parts of the world, particularly from Europe and the USA. This study investigated whether mutations in the ISDR of NS5A gene influence interferon efficacy in Chinese patients with chronic HCV-1b infection.
METHODS: Forty-five Chinese patients with chronic HCV infection were enrolled in a retrospective study. Of these patients, 20 with HCV-1b infection completed an interferon monotherapy course and 6-month follow-up. The pretreatment mutations in the nucleic acid sequence of NS5A 2209-2248 (ISDR) of HCV-1b were identified by sequencing RT-PCR products followed by comparison with the prototype sequence (HCV-J). Correlation with the clinical efficacy of interferon alpha therapy was then analyzed retrospectively.
RESULTS: The statistical analysis indicated a significant correlation between the mutations in ISDR of HCV-1b and sustained virological response to interferon alpha treatment (P < 0.05), and an association of the mutations in ISDR with the pretreatment serum alanine aminotransferase levels (P < 0.01) in Chinese patients with chronic HCV-1b infection.
CONCLUSIONS: The results support the concept that the response of HCV-1b infected patients towards interferon therapy is influenced by the mutations within the ISDR of NS5A gene.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17914967     DOI: 10.1111/j.1440-1746.2006.04566.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  7 in total

1.  Effects of mutation number in interferon sensitivity determining region on peripheral blood CD4(+) T cell subsets (Th1, Th2) in chronic hepatitis C patients with hepatitis C virus genotype 1b and high viral load.

Authors:  Koji Ishii; Mie Shinohara; Michio Kogame; Misato Shiratori; Katsuya Higami; Kaori Kanayama; Kazue Shiozawa; Noritaka Wakui; Hidenari Nagai; Manabu Watanabe; Yasukiyo Sumino
Journal:  Hepatol Int       Date:  2011-08-06       Impact factor: 6.047

Review 2.  Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis.

Authors:  Nathan Ford; Catherine Kirby; Kasha Singh; Edward J Mills; Graham Cooke; Adeeba Kamarulzaman; Philipp duCros
Journal:  Bull World Health Organ       Date:  2012-02-03       Impact factor: 9.408

Review 3.  Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy.

Authors:  Maria Victoria Preciado; Pamela Valva; Alejandro Escobar-Gutierrez; Paula Rahal; Karina Ruiz-Tovar; Lilian Yamasaki; Carlos Vazquez-Chacon; Armando Martinez-Guarneros; Juan Carlos Carpio-Pedroza; Salvador Fonseca-Coronado; Mayra Cruz-Rivera
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

4.  Predictors of virological response to a combination therapy with pegylated interferon plus ribavirin including virus and host factors.

Authors:  Namiki Izumi; Yasuhiro Asahina; Masayuki Kurosaki
Journal:  Hepat Res Treat       Date:  2010-09-05

Review 5.  Hepatitis C Virus: Viral Quasispecies and Genotypes.

Authors:  Kyoko Tsukiyama-Kohara; Michinori Kohara
Journal:  Int J Mol Sci       Date:  2017-12-22       Impact factor: 5.923

Review 6.  Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview.

Authors:  Ahmed El-Shamy; Hak Hotta
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

Review 7.  The role of HCV proteins on treatment outcomes.

Authors:  Kattareeya Kumthip; Niwat Maneekarn
Journal:  Virol J       Date:  2015-12-15       Impact factor: 4.099

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.